CBAY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CBAY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Operating Margin % is calculated as Operating Income divided by its Revenue. CymaBay Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-42.50 Mil. CymaBay Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.06 Mil. Therefore, CymaBay Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was -74,557.89%.
The historical rank and industry rank for CymaBay Therapeutics's Operating Margin % or its related term are showing as below:
CymaBay Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
CymaBay Therapeutics's Operating Income for the three months ended in Dec. 2023 was $-42.50 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $-101.68 Mil.
The historical data trend for CymaBay Therapeutics's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CymaBay Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Operating Margin % | Get a 7-Day Free Trial | - | - | - | - | -327.23 |
CymaBay Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Operating Margin % | Get a 7-Day Free Trial | - | - | -0.32 | - | -74,557.89 |
For the Biotechnology subindustry, CymaBay Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, CymaBay Therapeutics's Operating Margin % distribution charts can be found below:
* The bar in red indicates where CymaBay Therapeutics's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
CymaBay Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as
Operating Margin % | = | Operating Income (A: Dec. 2023 ) | / | Revenue (A: Dec. 2023 ) |
= | -101.679 | / | 31.073 | |
= | -327.23 % |
CymaBay Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as
Operating Margin % | = | Operating Income (Q: Dec. 2023 ) | / | Revenue (Q: Dec. 2023 ) |
= | -42.498 | / | 0.057 | |
= | -74,557.89 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CymaBay Therapeutics (NAS:CBAY) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Thank you for viewing the detailed overview of CymaBay Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Charles Mcwherter | officer: Chief Scientific Officer | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Daniel Menold | officer: Vice President, Finance | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Paul T Quinlan | officer: General Counsel | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Janet Dorling | director | C/O ACHAOGEN, INC., 1 TOWER PLACE, SUITE 300, SOUTH SAN FRANCISCO CA 94080 |
Sujal Shah | director, officer: Chief Executive Officer | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Kurt Von Emster | director | 601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080 |
Harish Shantharam | officer: Chief Financial Officer | 7575 GATEWAY BLVD, NEWARK CA 94560 |
Dennis D Kim | officer: Chief Medical Officer | C/O EMERALD BIOSCIENCE, INC., 130 NORTH MARINA DRIVE, LONG BEACH CA 90803 |
Eric Lefebvre | director | C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080 |
Thomas G Wiggans | director | |
Lewis J Stuart | officer: Chief Commercial Officer | 3172 PORTER DRIVE, PALO ALTO CA 94304 |
Venbio Select Advisor Llc | 10 percent owner | 110 GREENE STREET, SUITE 800, NEW YORK NY 10012 |
Behzad Aghazadeh | 10 percent owner | C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012 |
Carl Goldfischer | director | 161 WEST 61ST STREET, NEW YORK NY 10022 |
Robert James Wills | director | 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103 |
From GuruFocus
By Marketwired • 10-18-2023
By Marketwired • 11-06-2023
By Marketwired • 10-23-2023
By GuruFocus Research • 11-18-2023
By Marketwired • 08-28-2023
By GuruFocus Research • 10-11-2023
By Marketwired • 09-11-2023
By Marketwired • 09-14-2023
By GuruFocus Research • 01-23-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.